"The U.S. Food and Drug Administration today approved the first rapid Human Immunodeficiency Virus (HIV) test for the simultaneous detection of HIV-1 p24 antigen as well as antibodies to both HIV-1 and HIV-2 in human serum, plasma, and venous or f"...
Clinical Trials In Adults
Nephrolithiasis/urolithiasis, including flank pain with or without hematuria (including microscopic hematuria), has been reported in approximately 12.4% (301/2429; range across individual trials: 4.7% to 34.4%) of patients receiving CRIXIVAN at the recommended dose in clinical trials with a median follow-up of 47 weeks (range: 1 day to 242 weeks; 2238 patient-years follow-up). The cumulative frequency of nephrolithiasis events increases with duration of exposure to CRIXIVAN; however, the risk over time remains relatively constant. Of the patients treated with CRIXIVAN who developed nephrolithiasis/urolithiasis in clinical trials during the double-blind phase, 2.8% (7/246) were reported to develop hydronephrosis and 4.5% (11/246) underwent stent placement. Following the acute episode, 4.9% (12/246) of patients discontinued therapy. (See WARNINGS and DOSAGE AND ADMINISTRATION, Nephrolithiasis/Urolithiasis.)
Asymptomatic hyperbilirubinemia (total bilirubin ≥ 2.5 mg/dL), reported predominantly as elevated indirect bilirubin, has occurred in approximately 14% of patients treated with CRIXIVAN. In < 1% this was associated with elevations in ALT or AST.
Hyperbilirubinemia and nephrolithiasis/urolithiasis occurred more frequently at doses exceeding 2.4 g/day compared to doses ≤ 2.4 g/day.
Clinical adverse experiences reported in ≥ 2% of patients treated with CRIXIVAN alone, CRIXIVAN in combination with zidovudine or zidovudine plus lamivudine, zidovudine alone, or zidovudine plus lamivudine are presented in Table 10.
Table 10: Clinical Adverse Experiences Reported in ≥ 2%
|Adverse Experience||Study 028 Considered Drug-Related and of Moderate or Severe Intensity||Study ACTG 320 of Unknown Drug Relationship and of Severe or Life-threatening Intensity|
|CRIXIVAN plus Zidovudine Percent
|CRIXIVAN plus Zidovudine plus Lamivudine Percent
|Zidovudine plus Lamivudine Percent
|Body as a Whole|
|Hemic and Lymphatic System|
|Nervous System/ Psychiatric|
|Skin and Skin Appendage|
|Difficulty breathing/ dyspnea/ shortness of breath||0||0.6||0.3||1.8||1.0|
|*Including renal colic, and flank pain with and without hematuria|
In Phase I and II controlled trials, the following adverse events were reported significantly more frequently by those randomized to the arms containing CRIXIVAN than by those randomized to nucleoside analogues: rash, upper respiratory infection, dry skin, pharyngitis, taste perversion.
Selected laboratory abnormalities of severe or life-threatening intensity reported in patients treated with CRIXIVAN alone, CRIXIVAN in combination with zidovudine or zidovudine plus lamivudine, zidovudine alone, or zidovudine plus lamivudine are presented in Table 11.
Table 11: Selected Laboratory Abnormalities of Severe
or Life-threatening Intensity Reported in Studies 028 and ACTG 320
|Study 028 Considered Drug-Related and of Moderate or Severe Intensity||Study ACTG 320 of Unknown Drug Relationship and of Severe or Life-threatening Intensity|
|CRIXIVAN plus Zidovudine Percent
|CRIXIVAN plus Zidovudine plus Lamivudine Percent
|Zidovudine plus Lamivudine Percent
|Decreased hemoglobin < 7.0 g/dL||0.6||0.9||3.3||2.4||3.5|
|Decreased platelet count < 50 THS/mm³||0.9||0.9||1.8||0.2||0.9|
|Decreased neutrophils < 0.75 THS/mm³||2.4||2.2||6.7||5.1||14.6|
|Increased ALT > 500% ULN*||4.9||4.1||3.0||2.6||2.6|
|Increased AST > 500% ULN||3.7||2.8||2.7||3.3||2.8|
|Total serum bilirubin > 250% ULN||11.9||9.7||0.6||6.1||1.4|
|Increased serum amylase > 200% ULN||2.1||1.9||1.8||0.9||0.3|
|Increased glucose > 250 mg/dL||0.9||0.9||0.6||1.6||1.9|
|Increased creatinine > 300% ULN||0||0||0.6||0.2||0|
|*Upper limit of the normal range.|
Body As A Whole: redistribution/accumulation of body fat (see PRECAUTIONS, Fat Redistribution).
Cardiovascular System: cardiovascular disorders including myocardial infarction and angina pectoris; cerebrovascular disorder.
Hypersensitivity: anaphylactoid reactions; urticaria; vasculitis.
Musculoskeletal System: arthralgia, periarthritis.
Nervous System/Psychiatric: oral paresthesia; depression.
Skin and Skin Appendage: rash including erythema multiforme and Stevens-Johnson syndrome; hyperpigmentation; alopecia; ingrown toenails and/or paronychia; pruritus.
Urogenital System: nephrolithiasis/urolithiasis, in some cases resulting in renal insufficiency or acute renal failure, pyelonephritis with or without bacteremia (see WARNINGS); interstitial nephritis sometimes with indinavir crystal deposits; in some patients, the interstitial nephritis did not resolve following discontinuation of CRIXIVAN; renal insufficiency; renal failure; leukocyturia (see PRECAUTIONS), crystalluria; dysuria.
Read the Crixivan (indinavir sulfate) Side Effects Center for a complete guide to possible side effects
Indinavir is an inhibitor of the cytochrome P450 isoform CYP3A4. Coadministration of CRIXIVAN and drugs primarily metabolized by CYP3A4 may result in increased plasma concentrations of the other drug, which could increase or prolong its therapeutic and adverse effects (see CONTRAINDICATIONS and WARNINGS).
Indinavir is metabolized by CYP3A4. Drugs that induce CYP3A4 activity would be expected to increase the clearance of indinavir, resulting in lowered plasma concentrations of indinavir. Coadministration of CRIXIVAN and other drugs that inhibit CYP3A4 may decrease the clearance of indinavir and may result in increased plasma concentrations of indinavir.
Table 8: Drugs That Should Not Be Coadministered with
|Drug Class: Drug Name||Clinical Comment|
|Alpha 1-adrenoreceptor antagonist: alfuzosin||Potentially increased alfuzosin concentrations can result in hypotension.|
|Antiarrhythmics: amiodarone||CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.|
|Antimycobacterial: rifampin||May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors or other coadministered antiretroviral agents.|
|Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, methylergonovine||CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.|
|GI motility agents: cisapride||CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.|
|Herbal products: St. John’s wort (Hypericum perforatum)||May lead to loss of virologic response and possible resistance to CRIXIVAN or to the class of protease inhibitors.|
|HMG-CoA Reductase inhibitors: lovastatin, simvastatin||CONTRAINDICATED due to an increased risk for serious reactions such as myopathy including rhabdomyolysis.|
|Neuroleptic: pimozide||CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as cardiac arrhythmias.|
|PDE5 inhibitor: Revatio (sildenafil) [for treatment of pulmonary arterial hypertension]||A safe and effective dose has not been established when used with CRIXIVAN. There is increased potential for sildenafil-associated adverse events (which include visual disturbances, hypotension, prolonged erection, and syncope).|
|Protease inhibitor: atazanavir||Both CRIXIVAN and atazanavir are associated with indirect (unconjugated) hyperbilirubinemia. Combinations of these drugs have not been studied and coadministration of CRIXIVAN and atazanavir is not recommended.|
|Sedative/hypnotics: Oral midazolam, triazolam, alprazolam||CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.|
Table 9: Established and
Other Potentially Significant Drug Interactions: Alteration in Dose or Regimen
May Be Recommended Based on Drug Interaction Studies or Predicted Interaction
(See also CLINICAL PHARMACOLOGY for magnitude of interaction, WARNINGS and
DOSAGE AND ADMINISTRATION.)
|Drug Name||Effect||Clinical Comment|
|HIV Antiviral Agents|
|Delavirdine||↑ indinavir concentration||Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered when taking delavirdine 400 mg three times a day.|
|Didanosine||Indinavir and didanosine formulations containing buffer should be administered at least one hour apart on an empty stomach.|
|Efavirenz||↓indinavir concentration||The optimal dose of indinavir, when given in combination with efavirenz, is not known. Increasing the indinavir dose to 1000 mg every 8 hours does not compensate for the increased indinavir metabolism due to efavirenz.|
|Nelfinavir||↑ indinavir concentration||The appropriate doses for this combination, with respect to efficacy and safety, have not been established.|
|Nevirapine||↓ indinavir concentration||Indinavir concentrations may be decreased in the presence of nevirapine. The appropriate doses for this combination, with respect to efficacy and safety, have not been established.|
|The appropriate doses for this combination, with respect to efficacy and safety, have not been established. Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving indinavir in combination with ritonavir than those receiving CRIXIVAN 800 mg q8h.|
|Saquinavir||↑ saquinavir concentration||The appropriate doses for this combination, with respect to efficacy and safety, have not been established.|
|Antiarrhythmics: bepridil, lidocaine (systemic) and quinidine||↑antiarrhythmic agents concentration||Caution is warranted and therapeutic concentration monitoring is recommended for antiarrhythmics when coadministered with CRIXIVAN.|
|Anticonvulsants: carbamazepine, phenobarbital, phenytoin||↓ indinavir concentration||Use with caution. CRIXIVAN may not be effective due to decreased indinavir concentrations in patients taking these agents concomitantly.|
|Antidepressant: Trazodone||↑trazodone concentration||Concomitant use of trazodone and CRIXIVAN may increase plasma concentrations of trazodone. Adverse events of nausea, dizziness, hypotension and syncope have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as CRIXIVAN, the combination should be used with caution and a lower dose of trazodone should be considered.|
|Anti-gout: Colchicine||↑colchicine concentration||Patients with renal or hepatic impairment should not be given colchicine with CRIXIVAN.
Treatment of gout flares:
Co-administration of colchicine in patients on CRIXIVAN: 0.6 mg (1 tablet) x 1 dose, followed by 0.3 mg (half tablet) 1 hour later. Dose to be repeated no earlier than 3 days.
Prophylaxis of gout flares:
Co-administration of colchicine in patients on CRIXIVAN:
If the original colchicine regimen was 0.6 mg twice a day, the regimen should be adjusted to 0.3 mg once a day. If the original colchicine regimen was 0.6 mg once a day, the regimen should be adjusted to 0.3 mg once every other day.
Treatment of familial Mediterranean fever (FMF):
Co-administration of colchicine in patients on CRIXIVAN: Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day).
|Calcium Channel Blockers, Dihydropyridine: e.g., felodipine, nifedipine, nicardipine||↑ dihydropyridine calcium channel blockers concentration||Caution is warranted and clinical monitoring of patients is recommended.|
|The appropriate doses for this combination, with respect to efficacy and safety, have not been established.|
|Endothelin receptor antagonist: Bosentan||↑bosentan concentration||Co-administration of bosentan in patients on CRIXIVAN or coadministration of CRIXIVAN in patients on bosentan: Start at or adjust bosentan to 62.5 mg once daily or every other day based upon individual tolerability.|
|HMG-CoA Reductase Inhibitors: atorvastatin, rosuvastatin||↑atorvastatin concentration
|The atorvastatin and rosuvastatin doses should be carefully titrated; use the lowest dose necessary with careful monitoring during treatment with CRIXIVAN.|
|Immunosuppressants: cyclosporine, tacrolimus, sirolimus||↑immunosuppressant agents concentration||Plasma concentrations may be increased by CRIXIVAN.|
|Inhaled beta agonist: Salmeterol||↑salmeterol||Concurrent administration of salmeterol with CRIXIVAN is not recommended. The combination may result in increased risk of cardiovascular adverse events associated with salmeterol, including QT prolongation, palpitations and sinus tachycardia.|
|Inhaled/nasal steroid: Fluticasone||↑fluticasone concentration||Concomitant use of fluticasone propionate and CRIXIVAN may increase plasma concentrations of fluticasone propionate. Use with caution. Consider alternatives to fluticasone propionate, particularly for long-term use.
Fluticasone use is not recommended in situations where CRIXIVAN is coadministered with a potent CYP3A4 inhibitor such as ritonavir unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.
|Itraconazole||↑indinavir concentration||Dose reduction of CRIXIVAN to 600 mg every 8 hours is recommended when administering itraconazole concurrently.|
|Ketoconazole||↑ indinavir concentration||Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered.|
|Midazolam (parenteral administration)||↑midazolam concentration||Concomitant use of parenteral midazolam with CRIXIVAN may increase plasma concentrations of midazolam. Coadministration should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. Coadministration of oral midazolam with CRIXIVAN is CONTRAINDICATED (see Table 8).|
|Rifabutin||↓ indinavir concentration ↑rifabutin concentration||Dose reduction of rifabutin to half the standard dose and a dose increase of CRIXIVAN to 1000 mg every 8 hours are recommended when rifabutin and CRIXIVAN are coadministered.|
|Sildenafil||↑ sildenafil concentration (only the use of sildenafil at doses used for treatment of erectile dysfunction has been studied with CRIXIVAN)||May result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, syncope, visual disturbances, and priapism.
Use of sildenafil for pulmonary arterial hypertension (PAH):
Use of Revatio (sildenafil) is contraindicated when used for the treatment of pulmonary arterial hypertension (PAH) [see CONTRAINDICATIONS].
Use of sildenafil for erectile dysfunction:
Sildenafil dose should not exceed a maximum of 25 mg in a 48-hour period in patients receiving concomitant CRIXIVAN therapy. Use with increased monitoring for adverse events.
|Tadalafil||↑ tadalafil concentration||May result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, visual disturbances, and priapism.
Use of tadalafil for pulmonary arterial hypertension (PAH):
The following dose adjustments are recommended for use of Adcirca (tadalafil) with CRIXIVAN:
Co-administration of Adcirca in patients on CRIXIVAN or coadministration of CRIXIVAN in patients on Adcirca:
Start at or adjust Adcirca to 20 mg once daily. Increase to 40 mg once daily based upon individual tolerability.
Use of tadalafil for erectile dysfunction:
Tadalafil dose should not exceed a maximum of 10 mg in a 72-hour period in patients receiving concomitant CRIXIVAN therapy. Use with increased monitoring for adverse events.
|Vardenafil||↑vardenafil concentration||Vardenafil dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant indinavir therapy.|
|Venlafaxine||↓ indinavir concentration||In a study of 9 healthy volunteers, venlafaxine administered under steady-state conditions at 150 mg/day resulted in a 28% decrease in the AUC of a single 800 mg oral dose of indinavir and a 36% decrease in indinavir Cmax. Indinavir did not affect the pharmacokinetics of venlafaxine and ODV. The clinical significance of this finding is unknown.|
Read the Crixivan Drug Interactions Center for a complete guide to possible interactions
Last reviewed on RxList: 4/4/2016
Additional Crixivan Information
Crixivan - User Reviews
Crixivan User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.